Czuriga István
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Kardiológiai Klinika.
Orv Hetil. 2002 Sep 15;143(37):2117-28.
The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.
在过去十年中，急性心肌梗死的治疗发生了革命性变化。药理学和机械再灌注治疗的进展提高了心肌梗死患者的生存率。尽管血管重建技术已被证明可减少梗死面积和降低住院死亡率，但从心肌梗死中恢复的患者再次梗死、发生充血性心力衰竭和猝死的风险仍然增加。尽管有令人瞩目的技术进步，但生活方式的改变和药物干预仍然是心肌梗死后二级预防的关键组成部分。尽管再梗死和死亡的二级预防概念已经经过数十年的深入研究，但医生对预防性治疗的使用严重不足。本文旨在对心肌梗死后二级预防临床试验进行全面的、基于证据的综述，以期提高冠心病患者有效治疗方法的利用率。
